1. 1 F F F Glucosamine
2 F F F
3 F
4 08/09/10
5
6 (Glucosamine) F 95 F
7 F F F F F
8 F F F F F F
9 F crystalline form F F F F
10 F F (All forms of degenerative
11 osteoarticular disease) F
12 F (Primary) F F
13 (Secondary) F
14 F Cervical arthrosis, Coxofemoral arthrosis, Gonarthrosis, Dosal
15 Arthrosis, Lumbosacral arthrosis, Scapulohumeral arthrosis, Periarthritis,
16 Lumbago, Fractures, Osteoarticular dystrophies, Chronic and subacute arthritis
17 F F F F
18 F F( F F / ) 26 F 10
19 2552 F F F F 380 F F
20 3 F F F F ( ., 2553) F F F F
21 F FF F F F
22 F F
F 1

2. 1 F
2 F F F F F
3 F F
4 F F F
5
6 1. F F F
7 F
8 2. F F F F
9 3. F F F
10 F F
11 F F F meta-analysis randomized
12 controlled trials (RCT) F F . 2005-2010 F F 31
13 1 2553 F Pubmed Cochrane F keywords Glucosamine and
14 osteoarthritis inclusion criteria F F F 12
15 F F F F keywords F Glucosamine and cost-effectiveness
16 F Pubmed Cochrane F F F
17 F Google keywords Glucosamine and osteoarthritis F F
18 F F F F personal file F F 2
19 F
20 1 F F F
Keywords F PubMed Cochrane F F
Glucosamine and osteoarthritis 32 12 9
Glucosamine and cost-effectiveness 2 2 2
F 2

3. 1
2
3
4 1. F
5 F F FF ( 2) F
6 F F F (statistical non-significance, NS) F F
7 Western Ontario and McMaster Universities (WOMAC) pain WOMAC function
8 F F (Sawitzke et al.,2010, Lee et al.,2010, Kawasaki et al., 2008, Messier et al., 2007)
9 F (Rozendaal et al.,2009) F F Roland Morris Disability
10 Questionnaire (RMDQ) F EuroQol-5 (EQ-5D) F (Wilkens
11 et al.,2010)
12 2 F
F F
F F
F
Lee et al.(2010) Meta- Knee 1,502† GS vs JSW NS (1 year)
analysis placebo Small/moderate (3 years)
Sawitzke et al.(2010) RCT Knee 662 Glucosamine WOMAC pain NS
vs placebo WOMAC function
Wilkens et al (2010) RCT Lumbar 250 Glucosamine RMDQ NS
vs placebo EQ-5D
Rozendaal et al (2009)* RCT Hip 222 GS vs WOMAC pain NS
Rozendaal et al (2008) placebo WOMAC function
JSW
Sawitzke et al.(2008) RCT Knee 572 Glucosamine JSW NS
vs placebo
F 3

4. Kawasaki et al (2008) RCT Knee 142 GH vs JSW NS
placebo
Messier et al.(2007) RCT Knee 89 GH vs WOMAC function NS
placebo WOMAC pain
1 GH = Glucosamine Hydrochloride, GS = Glucosamine Sulfate
2 NS = Statistically non-significant difference
3 * Subgroup analysis
4 † Glucosamine F (Chondroitin) F
5 F F F F F F F F (joint
6 space width, JSW) F F F F F F F F
7 F F (Lee et al.,2010) F (Lee et al.,2010,Rozendaal et al,2009,
8 2008, Sawitzke et al.,2008, Kawasaki et al.,2008)
9 F F F F
10 (Bruyere et al., 2008) F F F F 2001
11 2002 (N=275 N=340) F intent to treat1 F F F
12 F F 5 F F 1 F
13 F F F F2
14 meta-analysis Towheed et al. (2009) RCT
15 25 F 4,963 F 1980 - 2008 F F F
16 F F F F F
17 F
18 2. F F F
19 F F F F2 (Black,2009
20 Scholtissen et al, 2010) (Black et al, 2009) Markov FF
1
F F F 1) F
F F F F F F F F F F F 2) F F FF F
F F F
2
F F F F
F 4

5. 1 Reginster (2001) Pavelka
(2002) F
2 Chaiyakunapruk (2010) F F F F F
3 F F F ( F
4 F NSAID COX-II) F F (incremental cost-effectiveness ratio, ICER) F
5 F 774,125 F (quality-adjusted life year, QALY)
6 F Viatril-S® F F 2,612,605 F F F
7 F F F F F ( F 1 GDP per capita 100,000 F ) F
8 (Scholtissen et al, 2010) F F RCT Reginster (2001)
9 Pavelka (2002) F F F F (utility) F
10 F F
11 3. F
12 F F
13 F F F F
14 F F F F FF
15 F
16 F F F
17 National Institute of Clinical Excellence (NICE3) guideline (2008) F F F
18 F F F (National Health Service, NHS)
19 F F F F F F F FF F
20 F F F F (NCPE, 2009, SMC, 2008, Mid Essex,2008,
21 Oxfordshire, 2008, Berkshire PC,2008, OxPF,2008, Suffolk PCT, 2008, North Staffordshire APC, 2008,
22 South Staffordshire APC, 2008, Worcestershire APC, 2008)
3
F F FF
F F
F 5

6. 1 F F (The Dental and
2 Pharmaceutical Benefits Agency, TLV) F F F
3 F F F F F (TLV, 2010)
4 F F
5 F FF F
6 F F F F F
7 F F
8 F F F F F F F F F F F
9
10 F F F
11 F F F F F
12 F F F F
13 F
14 ( .) (2553). F F
15 F 34 F F .
16 Sawitzke A, Shi H, Finco M, Dunlop D, Harris C, Singer N, et al. (2010). Clinical efficacy and safety of glucosamine,
17 chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results
18 from GAIT. Annals of the Rheumatic Diseases. Aug;69(8):1459-64.
19 Sawitzke A, Shi H, Finco M, Dunlop D, Bingham III C, Harris C, et al. (2008). The effect of glucosamine and/or chondroitin
20 sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention
21 trial. Arthritis & Rheumatism. 58(10):3183-91.
22 Kawasaki T, Kurosawa H, Ikeda H, Kim S, Osawa A, Takazawa Y, et al. (2008). Additive effects of glucosamine or
23 risedronate for the treatment of osteoarthritis of the knee combined with home exercise: a prospective randomized
24 18-month trial. Journal of bone and mineral metabolism. 26(3):279-87.
F 6

7. 1 Wilkens P, Scheel I, Grundnes O, Hellum C, Storheim K. (2010). Effect of glucosamine on pain-related disability in patients
2 with chronic low back pain and degenerative lumbar osteoarthritis: a randomized controlled trial. JAMA.
3 304(1):45.
4 Rozendaal R, Uitterlinden E, van Osch G, Garling E, Willemsen S, Ginai A, et al. (2009). Effect of glucosamine sulphate on
5 joint space narrowing, pain and function in patients with hip osteoarthritis; subgroup analyses of a randomized
6 controlled trial. Osteoarthritis and cartilage. 17(4):427-32.
7 Lee Y, Woo J, Choi S, Ji J. (2009). Effect of glucosamine or chondroitin sulphate on osteoarthritis progression: a meta-
8 analysis. Rheumatol Int. Jan(30(3)):357-63.
9 Scholtissen S, Bruyère O, Neuprez A, Severens JL, Herrero-Beaumont G, Rovati L, Hiligsmann M, Reginster JY.
10 (2010).Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with
11 paracetamol. Int J Clin Pract. May;64(6):756-62.
12 Chaiyakunapruk N, Saokaew S, Pansang S. (2010). Cost-Effectiveness Analysis of Glucosamine Sulphate for The Treatment
13 of Osteoarthritis in Thailand. 4th Asia Pacific International Society of Pharmacoeconomics and Outcomes
14 Research Sept 5th-7th, 2010 at Phuket, Thailand. (Oral Presentation).
15 Black C, Clar C, Henderson R, MacEachern C, McNamee P, Quayyum Z, Royle P, Thomas S. (2009). The clinical
16 effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of
17 the knee: a systematic review and economic evaluation. Health Technology Assessment. Nov;13(52):1-148.
18 Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. (2002). Glucosamine sulfate use and delay of
19 progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med.
20 162: 2113-23.
21 Reginster JY, Deroisy R, Rovati LC, et al. (2001.) Long-term effects of glucosamine sulphate on osteoarthritis progression: a
22 randomised, placebo-controlled clinical trial. Lancet ;357:251-6.
23 National Institute for Health and Clinical Excellence. (2008). Osteoarthritis: the care and management of osteoarthritis in
24 adult. London. Clinical guideline;no.59.
25 Towheed, T.E,.Maxwell, L.,Anastassisdes, T.P., Shea, B., Houpt, T., Robinson, V., Hochberg, M.C.&Wells,G.
26 (2009).Glucosamine therapy for treating osteoarthritis (Review). Cochrane Library.
F 7

8. 1 The National Centre for Pharmacoeconomics (NCPE) in Ireland. (2009). Economic evaluation of glucosamine sulfate
2 (DONA) for the treatment of osteoarthritis in the Irish healthcare setting. [online]. Dublin:NCPE. Available from :
3 http://www.ncpe.ie/u_docs//doc_171.pdf [Accessed 2 September 2010]
4 Scottish Medicines Consortium (SMC). (2008). Advice on glucosamine (as hydrochloride), 625mg tablets (Alateris®).
5 [online]. No. 471/08. Lothian:NHS Scotland. Available from :
6 http://www.scottishmedicines.org.uk/files/glucosamine%20%20Alateris%20FINAL%20May%202008%20for%20
7 website.pdf. [Accessed 2 September 2010]
8 Mid Essex Area Prescribing Committee. (2008). Glucosamine for osteoarthritis. [online].Mid Essex Locality. Available
9 from : http://www.midessex.nhs.uk/Documents
10 /Key%20Documents/Policies%20and%20Procedures/Medicines%20Management%20Policies%20and%20Procedu
11 res/Glucosamine%20Policy%20Statement.pdf. [Accessed 2 September 2010]
12 Oxfordshire Priorities Forum. (2008). Glucosamine (sulphate and hydrochloride salt) for adult osteoarthritis. [online].
13 Oxfordshire PCT. Available from : http://www.oxford
14 Berkshire Priorities Committee. (2008). Minutes of meeting on Glucosamine for OA knee. [online]. Berkshire. Available
15 from : http://www.berkshire.nhs.uk/priorities/ _policies/Minutes-3-September-2008.pdf. [Accessed 2 September
16 2010]
17 Suffolk PCT Drug & Therapeutics Committee. (2008). New Medicine Report. Glucosamine Hydrochloride (Alateris,
18 William Ransom & Son). [online]. Suffolk. Available from :
19 http://www.suffolkextranet.nhs.uk/LinkClick.aspx?fileticket=lgx4Q4L2EJs%3D&tabid=966&mid=1797.
20 [Accessed 2 September 2010]
21 North Staffordshire Area Prescribing Committee. (2008). New Medicine Review and Verdict. Glucosamine hydrochloride
22 (AlaterisTM). [online]. North Staffordshire. Available from :
23 http://www.medicinesmanagementstoke.nhs.uk/documents/Glucosamine_Ref_JAN08.pdf. [Accessed 2
24 September2010]
25 South Staffordshire APC.(2008).Glucosamine.[online]. South Staffordshire. Available
26 from:http://www.southstaffordshirepct.[Accessed 2 September 2010]
F 8

9. 1 Worcestershire APC. (2008). Recommendations for Prescription of Glucosamine for Osteoarthritis. [online]. Worcestershire
2 APC. Avialable from :http://www.worcspct.nhs.uk/publications/policies-and-procedures/medicine-management--
3 pharmacy /area-prescribing-committee.aspx#musculo. [Accessed 1 September 2010]
4 The Midlands Therapeutics Review and Advisory Committee (MTRAC).(2008). Glucosamine in osteoarthritis. [online].
5 Available from : http://www.nelm.nhs.uk/ en/NeLM-Area/Evidence/Drug-Specific-Reviews/MTRAC. [Accessed 1
6 September 2010]
7 The Swedish Dental and Pharmaceutical Benefits agency. Glucosamine excluded from the reimbursement system. Interim
8 decision from the review of painkillers and anti-inflammatory medicines. THE DECISIONS COME INTO FORCE
9 on 2010-05-15. [online]. Available from : http://tlv.se/Upload/Genomgangen/100517-tlv-interim-decision-
10 glucosamine.pdf. [Accessed 2 September 2010]
F 9